GermanyGermany

Cancer immunotherapeutics specialist immatics raises EUR54m

23.09.2010

Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.

GermanyGermany

13.05.2010

Martinsried – SuppreMol GmbH has enrolled the first patient in a Phase Ib/IIa clinical trial with SM101, a treatment for Idiopathic Thrombocytopenic Purpura (ITP). Up to 36 patients will receive 4 weekly doses of the recombinant,...

GermanyGermany

12.05.2010

Life Technologies PD-Direct® has partnered with Cytovance Biologics to demon­strate rapid process transfer and scale-up using new media developed for fed batch processes and DASGIP Bioreactors. The new media were developed by...

GermanyGermany

12.05.2010

Tübingen — German mRNA vaccine specialist CureVac GmbH has secured a 27.6 million euro financing round with Dievini Hopp BioTech Holding. The company has announced that it will use the proceeds to drive forward its programmes for...

GermanyGermany

04.05.2010

Berlin - On Monday, German NOXXON Pharma AG announced the successful completion of a Phase I trial with the 1st "Spiegelmer" NOX-A12, an antagonist of stromal cell-derived factor-1 (SDF-1). Final data analysis demonstrated an...

GermanyGermany

30.04.2010

Berlin/Chicago – Despite the financial crisis, the German biotechnology sector grew in the last year. According to a brand-new biotech-report commissioned by the German Research Ministry and published just a couple of days...

GermanyGermany

19.04.2010

Munster – Germany’s federal state North-Rhine Westfalia is to channel EUR 80million into the medical applications of stem cell research. On Friday, the country’s minister Juergen Ruettgers announced that the money will be used...

GermanyGermany

15.04.2010

Wuppertal – Bayer’s anti-infectives spin-out AiCuris has raised EUR 55 million in this year’s largest financing round of a German biotech company lead by the existing shareholders. The money will be used to push Aicuris clinical...

GermanyGermany

01.04.2010

Berlin - On March 30th, Berlin-based biomarker specialist Epigenomics, successfully raised EUR 33,1 million at the public market through the placement of 14,697,361 new shares. The offering started on March 15 at a subscription...

Displaying results 111 to 120 out of 454

< Previous 111-120 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/11/article/cancer-immunotherapeutics-specialist-immatics-raises-eur54-million.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3037.3%
  • GW PHARMACEUTICALS (UK)426.00 GBP667.6%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.28 CHF-91.7%
  • THROMBOGENICS (B)9.14 EUR-70.4%

No liability assumed, Date: 30.07.2014


Current issue

All issues

Product of the week

Products